Evanston, IL, United States of America

Richard I Morimoto

USPTO Granted Patents = 7 


 

Average Co-Inventor Count = 5.1

ph-index = 1


Company Filing History:


Years Active: 2006-2019

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: The Innovations of Richard I Morimoto

Introduction

Richard I Morimoto is a prominent inventor based in Evanston, IL (US). He has made significant contributions to the field of neurodegenerative diseases, particularly through his innovative research and development of pharmaceutical compositions. With a total of seven patents to his name, Morimoto's work has the potential to impact the treatment of conditions such as amyotrophic lateral sclerosis (ALS).

Latest Patents

Morimoto's latest patents include groundbreaking inventions aimed at treating amyotrophic lateral sclerosis. One of his notable patents focuses on the identification of compounds and pharmaceutical compositions for treating subjects with ALS and other neurodegenerative diseases. This invention also provides methods for preparing these compounds. Another significant patent involves cyclohexane-1,3-diones, which are also aimed at treating ALS and related conditions. This patent similarly outlines methods for preparing the identified CHD compounds.

Career Highlights

Throughout his career, Richard I Morimoto has worked with esteemed institutions such as Northwestern University and Cambria Pharmaceuticals, Inc. His research has garnered attention for its potential to advance the understanding and treatment of neurodegenerative diseases.

Collaborations

Morimoto has collaborated with notable colleagues, including Donald R Kirsch and Radhia Benmohamed. These partnerships have contributed to the depth and breadth of his research efforts.

Conclusion

Richard I Morimoto's innovative work in the field of neurodegenerative diseases exemplifies the impact of dedicated research and invention. His contributions through patents and collaborations continue to pave the way for advancements in treatment options for ALS and similar conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…